Drugmaker Mylan’s planned tie-up with the Upjohn unit of pharmaceutical giant Pfizer Inc. comes at a time of “massive and sustained generic price deflation,” according to an industry consultant.

Whether the as-yet unnamed Mylan-Upjohn outfit succeeds turns on how well Pfizer can essentially compete against itself in maximizing revenue from branded drugs losing their patent protection.

The outcome will determine the future of the new company’s facilities, including Mylan’s one-time executive offices in Cecil and a pharmaceutical manufacturing plant in Morgantown, W.Va., which have a combined employment of about 3,200 people. Both facilities are part of the new company’s future, but a Pfizer spokeswoman said it was too early to comment on future employment.

The all-stock deal announced last week, which still needs to go through regulatory and approval by Mylan shareholders, could create a new business with between $19 billion and $20 billion in annual revenues.

Advertise with us

The two new partners each make a lot of medicines that Americans have in their cabinets.

Among Pfizer’s branded products are the cholesterol-lowering drug Lipitor and male impotence medicine Viagra. China-based Upjohn, the name of a company Pfizer acquired years ago, has nine manufacturing centers in eight countries and it serves as Pfizer’s unit for off-patent branded and generic medicines. Mylan will complement UpJohn with its own rich pipeline of drugs losing patent protection.

The strategy

Here’s a peek at Pfizer’s strategy as described by industry experts.

A company with a patent for a medicine, which lasts 20 years from its invention, has priority in making a generic version. In this case, Pfizer is in a position of competing against itself when launching the less expensive copies of its branded drugs. After the original patent expires, a generic company can introduce its version of the patented drug for a six-month period before competitors can jump in, allowing Pfizer to squeeze every last dollar from its branded products.

Advertise with us

A combined Mylan-Upjohn will have capabilities across 165 markets, with Mylan strong in in medications for the central nervous system, anesthesia, infectious diseases and cardiovascular problems. Upjohn’s strength is iconic brands such as Lipitor, Celebrex and Viagra.

But efforts to stoke the Pfizer revenue machine will occur against a backdrop of “massive price deflation” of generic drugs since 2015, according to Adam Fein, CEO of Philadelphia-based Pembroke Consulting Inc.

Based on data from New York City independent research firm Nephron Research LLC, price deflation in oral solid generic pills was 10% to 15% through 2017 and 2018.

Last year alone, there were a record number of generic approvals by the Food & Drug Administration, a trend that has prompted some drug manufacturers to signal their intention to get out of highly competitive categories where prices have flatlined, Mr. Fein wrote in an investor reports.

End of the boom years

Advertise with us

The generic drug industry was born in 1984 with the Hatch-Waxman Act, which allowed the Food and Drug Administration to approve versions of brand name drugs without requiring repeat efficacy and safety research. Mylan rode the boom years that followed as consumers and health insurers demanded lower cost generic versions of brand drugs.

Increasing competition in the industry created overcapacity while prices were pushed down by the emergence of large drug buying groups, such as Foxborough, Mass.-based Red Oak Sourcing, the biggest generic drug purchasing group in the country. Red Oak was created in 2014 by Cardinal Health Inc. and CVS Caremark.

Big pharmaceutical buying groups, increased competition in the market and other factors cut earnings for generic manufacturers like Mylan, which has seen its stock price erode since 2015.

The good news: oral generic prices were expected to stabilize — and possibly rise — through 2019, Mr. Fein wrote.

Hard-to-copy products

Advertise with us

Mylan and Pfizer haven’t been sitting on their hands waiting for a “very mature” pharmaceutical market to improve, said Curt Wanek, biotech and pharma industry analyst at Bloomberg.

The new company’s road map is to shift focus, said Mr. Wanek, who described the new Mylan-Upjohn business in a note to investors as a “diversified powerhouse.”

“They want to get away from the commoditized solids,” he said Wednesday. “They want to make hard-to-copy products, inhalers and biosimilars,” which are medicines made from live cells. “Mylan has the best-in-class portfolio.”

If Mylan and Upjohn combine, the company “could be the most valuable specialty-generic drugmaker in the world,” Mr. Wanek wrote. Upjohn is a cash cow for Pfizer, generating a margin of about 70% before taxes, he said.

A debt millstone

Advertise with us

By comparison, Mylan comes with baggage in the form of debt totaling about $14 billion. Mylan’s debt millstone has thwarted the company’s commercial progress, Mr. Wanek said.

Mylan’s management also has been an issue, with criticism over the years for excessive corporate salaries and perks, including personal use of the corporate jet up to 70 hours annually for Chairman Robert J. Coury. His compensation in 2016 was $97.6 million, making him the highest paid executive in the region.

Mylan shareholders have tried to rein in potential executive abuses by backing a proposal in June to strengthen the company’s clawback policy, which forces top executives to return incentive pay in the case of misconduct. The nonbinding proposal was submitted by the UAW Retiree Medical Benefits Trust in Detroit.

Meanwhile, Mylan has been disappointing investors with delays in getting new products to market, Mr. Wanek said. “Delivery of commercials has been a failure to date,” he said. “These products become commoditized so fast,” giving competitors a head start and leaving Mylan to compete just on price.

Still outstanding is a civil lawsuit filed by 40 state attorneys general against Mylan and other generic drugmakers alleging that they colluded to fix prices for more than 100 drugs. Mylan has denied the claims.

Advertise with us

Mr. Coury will serve as executive chairman of the new company with CEO Michael Goettler, a native German who has an MBA from the University of Texas at Austin and is group leader at Upjohn. Mylan president Rajiv Malik will continue in the role of president in the new company.

During a call with investors Monday, Sanford C. Bernstein & Co. analyst Ronny Gal asked Mr. Coury a question about corporate governance his new role.

“So look, Ronny, I think all of our shareholders know one thing,” Mr. Coury said. “I don’t make up things, so if I tell you I’m going to do something, it’s done.”

Kris B. Mamula: kmamula@post-gazette.com or 412-263-1699

Correction, posted Aug. 6, 2019: Mylan’s outstanding debt has been corrected to $14 billion.